Drug Profile
Kahalalide F
Alternative Names: KF; PM 92102Latest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator PharmaMar
- Class Depsipeptides
- Mechanism of Action ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer; Malignant melanoma; Non-small cell lung cancer; Psoriasis
Most Recent Events
- 14 Apr 2022 No development reported - Phase-II for Non-small cell lung cancer (In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Spain (IV)
- 17 Jun 2009 No development reported - Phase-II for Liver cancer in Spain (IV)
- 17 Jun 2009 No development reported - Phase-II for Malignant melanoma in Europe (IV)